Phase 2/3 Rare Disease Deal Benchmarks

Median Upfront

$543M

Range: $289M - $790M

Total Deal Value

$2.4B

Range: $1.5B - $3.3B

Royalty Rate

8.9% - 17.9%

Tiered up to 21.9%

Dev Milestones

$295M

Range: $194M - $396M

Model Your Deal

Market Analysis

Phase 2/3 rare disease licensing deals carry a median total deal value of $2.4B, with upfront payments ranging from $289M to $790M. At this stage, deal structures are balanced between upfront and milestone payments, reflecting the proof-of-concept inflection. The recommended split allocates 23% to upfront and 77% to milestones.

The rare disease landscape at the phase 2/3 stage is characterized by limited competitive intensity per indication but growing platform competition. Development milestones average $295M, regulatory milestones contribute $424M, and commercial milestones reach $1.1B. Gene therapies and oligonucleotide-based approaches are transforming treatment paradigms, with orphan designations enabling premium pricing and accelerated regulatory paths.

Royalty rates for phase 2/3 rare disease deals range from 8.9% to 17.9% at the base tier, with high-tier escalation to 21.9%. Mid-stage royalties reflect the balance of de-risking achieved and remaining development investment.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average upfront payment for phase 2/3 rare disease deals?

Phase 2/3 rare disease deals average $543M in upfront payments, ranging from $289M to $790M. The upfront allocation of 23% of total deal value reflects the clinical stage risk profile.

How are phase 2/3 rare disease deal milestones structured?

Milestones account for approximately 77% of total deal value. Development milestones ($295M) represent the largest component, followed by commercial milestones ($1.1B) and regulatory milestones ($424M).

What royalty rates are typical for phase 2/3 rare disease licensing?

Base royalty rates range from 8.9% to 17.9%, with tiered escalation to 12.9%-21.9% on peak sales. Rates are influenced by modality, competitive positioning, and territorial scope.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Phase 2/3 Rare Disease Deal Benchmarks

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Preclinical Rare Disease Deals

Phase 1 Rare Disease Deals

Phase 2/3 Oncology Deals

Phase 2/3 Neurology Deals

Ready to Calculate Your Deal Terms?